Mazdutide Shows Promise in Controlling blood sugar and Obesity in Diabetes Patients: Study

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-03-10T20:15:32+05:30 | Updated On 10 March 2024 8:15 PM IST

Mazdutide, a dual agonist drug was found to target weight reduction and additionally to manage blood glucose levels in individuals with overweight and obesity. The key highlights of this study was published in the recent edition of Frontiers in Endocrinology.

Amidst the anticipation surrounding the efficacy of Mazdutide, the concerns regarding the scarcity of comprehensive evidence on its effectiveness and safety prevailed. To address this, a recent study by David Lubasi Nalisa and coulleagues was conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the impact of Mazdutide on weight reduction among adults with and without diabetes.

Analysis of seven RCTs involving a total of 680 participants revealed the superiority of Mazdutide over placebo in various aspects. The drug showed effectiveness in reducing body weight, systolic and diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein.

Mazdutide demonstrated positive effects in the management of hemoglobin A1c (HbA1c) and fasting plasma glucose levels in individuals with type 2 diabetes which underlines its potential as a multifaceted therapeutic approach.

Further analysis through subgroup and meta-regression analyses unveiled nuances, where weight reduction was notable and more significant in non-diabetic individuals when compared to the diabetics, especially among the individuals who were undergoing longer treatment durations (24 weeks).

The outcomes of this study also highlighted a pertinent concern regarding the safety profile of Mazdutide. While the drug expressed promising efficacy, the participants reported transient mild to moderate gastrointestinal side effects which suggests a need for careful monitoring and management strategies.

Reference:

Nalisa, D. L., Cuboia, N., Dyab, E., Jackson, I. L., Felix, H. J., Shoki, P., Mubiana, M., Oyedeji-Amusa, M., Azevedo, L., & Jiang, H. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. In Frontiers in Endocrinology (Vol. 15). Frontiers Media SA. https://doi.org/10.3389/fendo.2024.1309118

Frontiers in EndocrinologymazdutideObesity management

Source : Frontiers in Endocrinology

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751